[go: up one dir, main page]

WO1997048815A3 - Methode pour ameliorer le transfert de genes - Google Patents

Methode pour ameliorer le transfert de genes Download PDF

Info

Publication number
WO1997048815A3
WO1997048815A3 PCT/EP1997/003152 EP9703152W WO9748815A3 WO 1997048815 A3 WO1997048815 A3 WO 1997048815A3 EP 9703152 W EP9703152 W EP 9703152W WO 9748815 A3 WO9748815 A3 WO 9748815A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene transfer
cells
hscs
hydroxyurea
enhancing gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/003152
Other languages
English (en)
Other versions
WO1997048815A2 (fr
Inventor
Nobuko Uchida
Ann Tsukamoto
Irving Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Systemix Inc
Original Assignee
Ciba Geigy AG
Novartis AG
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG, Systemix Inc filed Critical Ciba Geigy AG
Priority to EP97929200A priority Critical patent/EP0914461A2/fr
Priority to AU33394/97A priority patent/AU3339497A/en
Priority to JP50225698A priority patent/JP2001505043A/ja
Priority to IL12741697A priority patent/IL127416A0/xx
Publication of WO1997048815A2 publication Critical patent/WO1997048815A2/fr
Publication of WO1997048815A3 publication Critical patent/WO1997048815A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode qui permet d'optimiser le transfert de gènes dans les cellules souches hématopoiétiques multipotentes (CFU-S) en mettant lesdites cellules, avant le transfert, en contact avec de l'hydroxyurée, de façon à pousser les cellules en phase 0 à passer dans le cycle cellulaire actif. Cette méthode est utile pour traiter des patients atteints d'une maladie pouvant être convenablement traitée par thérapie génique ou mettant en jeu les cellules hématopoiétiques. L'invention concerne également une méthode qui permet d'accroître l'efficacité des greffes de moelle osseuse en administrant de l'hydroxyurée, ce qui accroît la formation de CFU-S.
PCT/EP1997/003152 1996-06-17 1997-06-17 Methode pour ameliorer le transfert de genes Ceased WO1997048815A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97929200A EP0914461A2 (fr) 1996-06-17 1997-06-17 Methode pour ameliorer le transfert de genes
AU33394/97A AU3339497A (en) 1996-06-17 1997-06-17 Method for enhancing gene transfer
JP50225698A JP2001505043A (ja) 1996-06-17 1997-06-17 遺伝子導入
IL12741697A IL127416A0 (en) 1996-06-17 1997-06-17 Method for enhancing gene transfer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/664,358 US5928638A (en) 1996-06-17 1996-06-17 Methods for gene transfer
US08/664,358 1996-06-17

Publications (2)

Publication Number Publication Date
WO1997048815A2 WO1997048815A2 (fr) 1997-12-24
WO1997048815A3 true WO1997048815A3 (fr) 1998-03-26

Family

ID=24665674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/003152 Ceased WO1997048815A2 (fr) 1996-06-17 1997-06-17 Methode pour ameliorer le transfert de genes

Country Status (7)

Country Link
US (1) US5928638A (fr)
EP (1) EP0914461A2 (fr)
JP (1) JP2001505043A (fr)
AU (1) AU3339497A (fr)
CA (1) CA2257880A1 (fr)
IL (1) IL127416A0 (fr)
WO (1) WO1997048815A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025398A2 (fr) * 1999-10-01 2001-04-12 Biotransplant Incorporated Technique permettant d'induire une tolerance fonctionnelle a des produits de transfert genique
WO2002010364A2 (fr) * 2000-07-27 2002-02-07 University Of Delaware Methodes d'augmentation de l'alteration genetique ciblee via des oligonucleotides
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20030095952A1 (en) * 2001-06-13 2003-05-22 Krause Diane S. Multi-organ engraftment with a single bone marrow-derived stem cell
AU2002341905A2 (en) * 2001-09-27 2003-04-07 University Of Delaware Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
ES2195751B1 (es) * 2001-11-27 2005-04-01 Universidad De Salamanca (Otri) Mamiferos no humanos transgenicos como modelos para patologias humanas con origen en celulas stem.
IL163875A0 (en) * 2002-03-07 2005-12-18 Univ Delaware Methods, compositions, and kits for enhancing oli gonucleotide mediated nucleic acid sequence alteration using compositions comprising a histone de
US20090217404A1 (en) * 2002-09-27 2009-08-27 Lowe Scott W Cell-based RNA interference and related methods and compositions
WO2004063356A2 (fr) * 2003-01-13 2004-07-29 Rao Mahendra S Molecule candidate a expression persistante dans des cellules souches et progenitrices destinee a l'apport de produits therapeutiques
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
DK1599573T3 (da) * 2003-02-17 2013-07-08 Cold Spring Harbor Lab Model til at studere genernes rolle i tumorresistens over for kemoterapi
US20090186839A1 (en) * 2003-02-17 2009-07-23 Cold Spring Harbor Laboratory Model for studying the role of genes in chemoresistance
WO2004090120A2 (fr) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Cellules souches presentant une sensibilite accrue a un chimioattracteur, et leurs procedes d'obtention et d'utilisation
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
AU2004263865B2 (en) 2003-08-08 2007-05-17 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US7534775B2 (en) * 2004-04-08 2009-05-19 Sangamo Biosciences, Inc. Methods and compositions for modulating cardiac contractility
JP4903689B2 (ja) * 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
US8236771B2 (en) * 2004-05-18 2012-08-07 National Institute Of Transplantation Foundation Vectors and methods for long-term immune evasion to prolong transplant viability
US20080131962A1 (en) * 2006-05-25 2008-06-05 Sangamo Biosciences, Inc. Engineered cleavage half-domains
CA2579292A1 (fr) * 2004-09-03 2006-03-23 The Scripps Research Institute Cellules souches hematopoietiques de lignees negatives isolees et methodes de traitement associees
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
WO2007053184A2 (fr) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methode de production de micro-arns
JP2009502170A (ja) 2005-07-26 2009-01-29 サンガモ バイオサイエンシズ インコーポレイテッド 外来核酸配列の標的化された組込み及び発現
EP2018424A2 (fr) * 2006-05-19 2009-01-28 Sangamo BioSciences, Inc. Procédés et compositions pour inactivation de la dihydrofolate réductase
AU2008275649B2 (en) 2007-07-12 2013-09-05 Sangamo Therapeutics, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2910568B1 (fr) 2008-06-10 2018-08-22 Sangamo Therapeutics, Inc. Procédés et composicions pour la génération de lignées cellulaires déficientes en BAX et BAK
WO2010021692A1 (fr) 2008-08-22 2010-02-25 Sangamo Biosciences, Inc. Procédés et compositions pour un clivage simple brin ciblé et une intégration ciblée
PT2334794T (pt) 2008-09-15 2017-02-15 Harvard College Modulação de bcl11a para tratamento de hemoglobinopatias
KR101673566B1 (ko) 2008-10-29 2016-11-07 상가모 바이오사이언스 인코포레이티드 글루타민 신테타제 유전자 발현을 불활성화시키기 위한 방법 및 조성물
CA2742876C (fr) * 2008-11-06 2018-08-21 Indiana University Research & Technology Corporation Materiaux et procedes ameliorant les protocoles de prise de greffe de cellules souches hematopoietiques
US8551945B2 (en) * 2009-02-04 2013-10-08 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
WO2010117464A1 (fr) * 2009-04-09 2010-10-14 Sangamo Biosciences, Inc. Intégration ciblée dans des cellules souches
CA2769262C (fr) 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Procedes et compositions de traitement de troubles de repetition tri-nucleotidique
EP2534173B1 (fr) 2010-02-08 2019-09-11 Sangamo Therapeutics, Inc. Demi-domaines de clivage techniques
AU2011215557B2 (en) 2010-02-09 2016-03-10 Sangamo Therapeutics, Inc. Targeted genomic modification with partially single-stranded donor molecules
EP2571512B1 (fr) 2010-05-17 2017-08-23 Sangamo BioSciences, Inc. Nouvelles protéines se liant à l'adn et leurs utilisations
CA2865011C (fr) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Procedes et compositions permettant de traiter la maladie de huntington
WO2014059173A2 (fr) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. Composés modifiant les lymphocytes t et leurs utilisations
ES2708948T3 (es) 2012-11-27 2019-04-12 Childrens Medical Ct Corp Elementos reguladores distales de bcl11a como dianas para la reinducción de la hemoglobina fetal
AU2014218621B2 (en) 2013-02-25 2019-11-07 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
EP3068905A4 (fr) 2013-11-11 2017-07-05 Sangamo BioSciences, Inc. Méthodes et compositions pour traiter la maladie de huntington
JP6594891B2 (ja) 2014-03-18 2019-10-23 サンガモ セラピューティクス， インコーポレイテッド ジンクフィンガータンパク質発現を調節するための方法および組成物
EP3598984B1 (fr) 2014-04-25 2024-04-10 The Children's Medical Center Corporation Compositions et procédés pour le traitement d'hémoglobinopathies
CA2947035A1 (fr) 2014-05-08 2015-11-12 Sangamo Biosciences, Inc. Methodes et compositions de traitement de la maladie de huntington
JP7288302B2 (ja) 2015-05-08 2023-06-07 ザ チルドレンズ メディカル センター コーポレーション 胎児型ヘモグロビン再誘導のための、ｂｃｌ１１ａエンハンサー機能性領域を標的とする方法
FI3352776T3 (fi) 2015-09-23 2025-07-08 Sangamo Therapeutics Inc Htt-repressoreita ja niiden käyttötapoja
CN108699132B (zh) 2015-12-18 2023-08-11 桑格摩生物治疗股份有限公司 Mhc细胞受体的靶向破坏
CA3008413A1 (fr) 2015-12-18 2017-06-22 Sangamo Therapeutics, Inc. Disruption ciblee du recepteur des lymphocytes t
EP3504327B1 (fr) 2016-08-24 2021-10-06 Sangamo Therapeutics, Inc. Nucléases spécifiques de cible spécifiquement modifiées
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
US12350284B2 (en) 2018-05-02 2025-07-08 The Children's Medical Center Corporation BCL11A microRNAs for treating hemoglobinopathies
SG11202101801RA (en) 2018-08-23 2021-03-30 Sangamo Therapeutics Inc Engineered target specific base editors
US20210317430A1 (en) 2018-09-18 2021-10-14 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
JP7762563B2 (ja) 2018-10-02 2025-10-30 サンガモ セラピューティクス， インコーポレイテッド タウタンパク質のモジュレーションのための方法および組成物
CN115667530A (zh) 2020-03-24 2023-01-31 世代生物公司 非病毒dna载体和其用于表达因子ix治疗剂的用途
KR20230003478A (ko) 2020-03-24 2023-01-06 제너레이션 바이오 컴퍼니 비-바이러스성 dna 벡터 및 고셰 치료제 발현을 위한 이의 용도
TW202515898A (zh) 2023-06-30 2025-04-16 日商武田藥品工業股份有限公司 Ｈｔｔ抑制物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019660A1 (fr) * 1992-04-03 1993-10-14 Baylor College Of Medicine Therapie genique utilisant l'intestin
CA2086844A1 (fr) * 1993-01-07 1994-07-08 Ian D. Dube Methode et produit de transfert de genes dans des cellules
EP0662512A2 (fr) * 1993-12-20 1995-07-12 Becton, Dickinson and Company Cellules souches hématopoiétiques humaines
WO1995033824A1 (fr) * 1994-06-06 1995-12-14 Fred Hutchinson Cancer Research Center Procede pour augmenter la transduction des cellules par des vecteurs du virus adeno-associe
WO1996009400A1 (fr) * 1994-09-19 1996-03-28 Systemix, Inc. Procedes permettant de modifier genetiquement des cellules souches hematopoietiques

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
ATE188740T1 (de) * 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
JP3386823B2 (ja) * 1991-03-28 2003-03-17 株式会社日立製作所 ファイルの管理方法及び装置
ATE169031T1 (de) * 1991-04-05 1998-08-15 Univ Washington Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
US6353150B1 (en) * 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993014188A1 (fr) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible
EP0652703A4 (fr) * 1992-07-28 1996-05-29 Steven Kessler Methodes d'immunoselection positive de cellules souches.
WO1994009363A1 (fr) * 1992-10-14 1994-04-28 Board Of Regents, The University Of Texas System Diagnostic et therapie contre le cancer
DE69333471T2 (de) * 1992-11-09 2005-02-24 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Erzielbare vektorenpartikel
USRE40811E1 (en) * 1992-11-13 2009-06-30 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
CA2170357A1 (fr) * 1993-08-25 1995-03-02 David Digiusto Methode pour l'obtention d'une population tres enrichie en cellules souches hematopoietiques
US5409813A (en) * 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
JP3253966B2 (ja) * 1993-10-06 2002-02-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 幹細胞増殖因子
AU7976294A (en) * 1993-11-05 1995-05-23 Regents Of The University Of California, The Improved postanatal and (in utero) fetal hematopoietic stem cell transplantation methods
JPH09507839A (ja) * 1993-12-03 1997-08-12 ジェネティック セラピー，インコーポレイテッド 胎児のための子宮内遺伝子治療
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019660A1 (fr) * 1992-04-03 1993-10-14 Baylor College Of Medicine Therapie genique utilisant l'intestin
CA2086844A1 (fr) * 1993-01-07 1994-07-08 Ian D. Dube Methode et produit de transfert de genes dans des cellules
EP0662512A2 (fr) * 1993-12-20 1995-07-12 Becton, Dickinson and Company Cellules souches hématopoiétiques humaines
WO1995033824A1 (fr) * 1994-06-06 1995-12-14 Fred Hutchinson Cancer Research Center Procede pour augmenter la transduction des cellules par des vecteurs du virus adeno-associe
WO1996009400A1 (fr) * 1994-09-19 1996-03-28 Systemix, Inc. Procedes permettant de modifier genetiquement des cellules souches hematopoietiques

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
B.J. KENNEDY: "The evolution of hydroxyurea therapy in chronic myelogenous leukemia", SEMINARS IN ONCOLOGY, vol. 19 (suppl. 9), no. 3, 1992, PHILADELPHIA, PA, US, pages 21 - 26, XP002046092 *
B.K. BHUYAN ET AL.: "Cell-kill kinetics of several S-phase-specific drugs", CANCER RESEARCH, vol. 33, 1973, CHICAGO, ILL, US, pages 888 - 894, XP002046094 *
D.M. BODINE ET AL.: "SURVIVAL OF RETROVIRUS INFECTION OF MURINE HEMATOPOIETIC STEM CELLS IN VITRO: EFFECTS OF 5-FU AND METHOD OF INFECTION", EXPERIMENTAL HEMATOLOGY, vol. 19, 1991, CHARLOTTESVILLE, VA, US, pages 206 - 212, XP002046091 *
D.W. RUSSELL ET AL.: "DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, 1995, WASHINGTON DC, US, pages 5719 - 5723, XP002046090 *
M. TAKAHASHI ET AL.: "Efficient introduction of a gene into hematopoietic cells in S-phase by electroporation", EXPERIMENTAL HEMATOLOGY, vol. 19, no. 5, - 1991, CHARLOTTESVILLE, VA,US, pages 343 - 346, XP002046146 *
T. YORIFUJI ET AL.: "The effect of cell synchronization on the efficiency of stable gene transfer by electroporation", FEBS LETTERS, vol. 245, no. 1,2, 1989, AMSTERDAM, NL, pages 201 - 203, XP002046089 *

Also Published As

Publication number Publication date
CA2257880A1 (fr) 1997-12-24
EP0914461A2 (fr) 1999-05-12
US5928638A (en) 1999-07-27
JP2001505043A (ja) 2001-04-17
IL127416A0 (en) 1999-10-28
AU3339497A (en) 1998-01-07
WO1997048815A2 (fr) 1997-12-24

Similar Documents

Publication Publication Date Title
WO1997048815A3 (fr) Methode pour ameliorer le transfert de genes
WO1998021334A3 (fr) Anticorps mg1 reconnaissant un petit sous-ensemble de cellules hematopoietiques humaines
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
MX340738B (es) Terapia para deficiencia de a-galactosidasa a.
NO963742L (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
NO971355L (no) Fotodynamiske terapi i selektiv celleinaktivering i blod og behandling av immundysfunksjons-sykdommer
WO1999049015A3 (fr) Cellules souches d'origine cardiaque
IL177228A0 (en) Use of a vector for the manufacture of a medicament for treating gaucher disease
ATE454166T1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
AU5585598A (en) Therapeutic uses for nitric oxide inhibitors
EP1367899A4 (fr) Cellules souches adultes totipotentes, sources de ces cellules, procedes d'obtention et de maintien de ces dernieres, procedes de differentiation de ces cellules, procedes d'utilisation correspondants et cellules derivees des cellules susmentionnees
DE60031456D1 (de) Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
MX9708854A (es) Terapia de genes para regulacion de celulas efectoras.
MY134778A (en) Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
WO1995027512A3 (fr) Compositions et procedes de therapie genique pour traiter des maladies
NO924309L (no) Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna
HUS1900041I1 (hu) Treoszulfán alkalmazása betegek csontvelõ- és vér õssejt-transzplantáció elõtti kondicionálására
GR3031229T3 (en) Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
AP2003002785A0 (en) Treatment of t cell disorders
EA200100342A1 (ru) Связывающие соединения адгезионной молекулы нервной клетки
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
WO1999033979A3 (fr) Proteines secretees par la moelle osseuse et polynucleotides
CA2323213A1 (fr) Traitement des maladies respiratoires et de l'otite moyenne
WO2003056897A3 (fr) Beta-glucocerebrosidase d'acide fortement phosphoryle et methodes de traitement de la maladie de gaucher

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997929200

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 333189

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2257880

Country of ref document: CA

Ref country code: CA

Ref document number: 2257880

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 502256

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997929200

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997929200

Country of ref document: EP